Replimune Wins 10-3 FDA Panel Vote for Melanoma Drug RP1

An FDA advisory panel backed Replimune's RP1 by 10 to 3, overriding agency reviewers, with an approval decision due August 2nd. Also: the same-day panel voted Capricor's Duchenne cell therapy deramiocel down 9 to 3, Johnson & Johnson took a $2.58 billion option on Flagship's in vivo CAR-T biotech Sail Biomedicines, Pfizer's Litfulo hit both Phase 3 endpoints in vitiligo, Eli Lilly's $2.8 billion AtaiBeckley deal drew competing bidders in treatment-resistant depression, Alnylam fell 29% on Amvuttra, and the FTC sued Hims & Hers. Visit us at thepharmacloseout.com.